速递｜联邦制药：收到诺和诺德12.93亿预付款

Core Viewpoint - The announcement highlights a significant collaboration between Federal Pharmaceutical and Novo Nordisk, focusing on the development of the drug UBT251, which targets multiple receptors for treating obesity and type 2 diabetes [2][4]. Group 1: Financial Aspects - Federal Pharmaceutical's subsidiary, Federal Biotechnology, received a prepayment of $180 million from Novo Nordisk, equivalent to approximately 1.293 billion RMB after Danish tax deductions [2]. - The collaboration agreement allows Federal Biotechnology to potentially receive a total of $200 million in prepayments and up to $1.8 billion in milestone payments based on the drug's development and commercialization progress [4]. Group 2: Drug Development and Rights - UBT251 is currently in clinical development and operates through a triple mechanism targeting GLP-1, GIP, and glucagon receptors, aimed at treating obesity, type 2 diabetes, and other metabolic diseases [4]. - Novo Nordisk will hold exclusive rights for the development, production, and commercialization of UBT251 globally, excluding Greater China, while Federal Biotechnology retains rights in the Greater China region [4].